{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:20Z","timestamp":1787027060175,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Mineralocorticoid receptor antagonists (MRA) improve outcomes in chronic kidney disease (CKD) and acute myocardial infarction (AMI) patients. However, the lack of evidence regarding long-term clinical outcomes in the use of MRA, including spironolactone, in patients with AMI combined with CKD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives:<\/jats:bold>\n                    This study aimed to investigate whether spironolactone could significantly reduce the risk of all-cause mortality and re-admission in patients with AMI and CKD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    In this single center, observational, retrospective, registry based clinical study, a total of 2,465 AMI patients were initially screened; after excluding patients with estimated glomerular filtration rate more than 60\u00a0ml\/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    , 360 patients in the standard treatment group and 200 patients in the spironolactone group met the criteria. All enrolled patients follow-up for 30 months. The primary outcomes were all-cause mortality and re-admission. The key safety outcome was hyperkalemia rates during the 30 months follow-up period.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    160 (44.4%) and 41 (20.5%) patients in the standard treatment and spironolactone groups died, respectively [hazard ratio (HR): 0.389; 95% confidence interval (CI): 0.276\u20130.548;\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001]. Re-admission occurred in 217 (60.3%) and 95 (47.5%) patients in the standard treatment and spironolactone groups, respectively (HR: 0.664; 95% CI: 0.522\u20130.846;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004). The spironolactone group was divided into two based on the daily dose, low dose group (no more than 40\u00a0mg) and high dose group (more than 40\u00a0mg); the differences in the mortality rate between low dose group (16.7%) and the standard treatment group (44.4%) (HR: 0.309; 95% CI: 0.228\u20130.418;\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) and high dose group (34.1%) (HR: 0.429; 95% CI: 0.199\u20130.925;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.007) were significant. The differences in re-hospitalization rate between low dose group (43.6%) and the standard treatment group (60.3%) (HR: 0.583; 95% CI: 0.457\u20130.744;\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) and high dose group (61.4%) (HR: 0.551; 95% CI: 0.326\u20130.930;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.007) was significant. Hyperkalemia occurred in 18 (9.0%) and 18 (5.0%) patients in the spironolactone group and standard treatment group, respectively (HR: 1.879; 95% CI: 0.954\u20133.700;\n                    <jats:italic>p<\/jats:italic>\n                    = 0.068). Whereas, Hyperkalemia occurred in high dose group (20.5%) significantly more often than in the standard treatment group (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) and low dose group (5.8%) (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.003).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Using MRA, such as spironolactone, may substantially reduce the risk of both all-cause mortality and re-admission in patients with AMI and CKD; the use of low-dose spironolactone has the best efficacy and safety. However, this was a relatively small sample size, single center, observational, retrospective, registry based clinical study and further prospective evaluation in adequately powered randomized trials were needed before further use of spironolactone in AMI with CKD population.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.632978","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T03:48:51Z","timestamp":1622432931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiang","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoshu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiafei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/nejmoa041365","article-title":"Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and Safety of Spironolactone in Patients with HFpEF and Chronic Kidney Disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early Aldosterone Blockade in Acute Myocardial Infarction","volume":"67","author":"Beygui","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1161\/circulationaha.106.634626","article-title":"High Plasma Aldosterone Levels on Admission Are Associated with Death in Patients Presenting with Acute ST-Elevation Myocardial Infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ahj.2008.12.013","article-title":"Aldosterone and long-term outcome after myocardial infarction: A substudy of the French nationwide Observatoire sur la Prise en charge hospitali\u00e8re, l'Evolution \u00e0 un an et les caRact\u00e9ristiques de patients pr\u00e9sentant un infArctus du myocarde avec ou sans onde Q (OPERA) study","volume":"157","author":"Beygui","year":"2009","journal-title":"Am. Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term Effects of Spironolactone on Proteinuria and Kidney Function in Patients with Chronic Kidney Disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2017.09.010","article-title":"Mineralocorticoid Receptor Antagonists in Patients with Acute Myocardial Infarction - A Systematic Review and Meta-Analysis of Randomized Trials","volume":"195","author":"Bossard","year":"2018","journal-title":"Am. Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","article-title":"Mineralocorticoid Receptor Antagonist Pre-treatment and Early post-treatment to Minimize Reperfusion Injury after ST-Elevation Myocardial Infarction: The MINIMIZE STEMI Trial","volume":"211","author":"Bulluck","year":"2019","journal-title":"Am. Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-dependent ESRD (SPin-D): a Randomized, Placebo-Controlled, Multiple Dosage Trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.296.11.1377","article-title":"Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease","volume":"296","author":"Coca","year":"2006","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2018.0850","article-title":"Aldosterone Antagonist Therapy and Mortality in Patients with ST-Segment Elevation Myocardial Infarction without Heart Failure","volume":"178","author":"Dahal","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","article-title":"Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients with Renal Dysfunction","volume":"67","author":"Evans","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/circulationaha.109.865352","article-title":"Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction in Patients with Chronic Kidney Disease","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/nejmoa041031","article-title":"Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/nejmoa040135","article-title":"Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/hrt.2010.215459","article-title":"Effects of Spironolactone on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodelling after Reperfusion Therapy in Patients with First ST-Segment Elevation Myocardial Infarction","volume":"97","author":"Kasama","year":"2011","journal-title":"Heart"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jacc.2017.07.783","article-title":"Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality after Acute Myocardial Infarction","volume":"70","author":"Korhonen","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early Eplerenone Treatment in Patients with Acute ST-Elevation Myocardial Infarction without Heart Failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur. Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for Heart Failure with Preserved Ejection Fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone Reduces Mortality 30 Days after Randomization Following Acute Myocardial Infarction in Patients with Left Ventricular Systolic Dysfunction and Heart Failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of Aldosterone- and Angiotensin II-Induced Target Organ Damage and Prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"B25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","article-title":"Summary of Recommendation Statements","volume":"3","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.gheart.2012.08.001","article-title":"Third Universal Definition of Myocardial Infarction","volume":"7","author":"Thygesen","year":"2012","journal-title":"Glob. Heart"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1681\/asn.2005101085","article-title":"Chronic Kidney Disease and Mortality Risk: a Systematic Review","volume":"17","author":"Tonelli","year":"2006","journal-title":"Jasn"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients with Severe Heart Failure","volume":"60","author":"Vardeny","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/1755-5922.12006","article-title":"Does Spironolactone Have a Dose-dependent Effect on Left Ventricular Remodeling in Patients with Preserved Left Ventricular Function after an Acute Myocardial Infarction?","volume":"31","author":"Vatankulu","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"c1768","DOI":"10.1136\/bmj.c1768","article-title":"Spironolactone Use and Renal Toxicity: Population Based Longitudinal Analysis","volume":"340","author":"Wei","year":"2010","journal-title":"BMJ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1009492","article-title":"Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.632978\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T03:48:55Z","timestamp":1622432935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.632978\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":31,"alternative-id":["10.3389\/fphar.2021.632978"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.632978","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"article-number":"632978"}}